• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞生长及利福平依赖性杀伤动力学的数学模型

Mathematical Model for Growth and Rifampicin-Dependent Killing Kinetics of Cells.

作者信息

Elitas Meltem, Kalayci Demir Guleser, Vural Kaymaz Sumeyra

机构信息

Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul 34956, Turkiye.

Faculty of Engineering, Department of Electrical and Electronics Engineering, Dokuz Eylul University, Izmir 35397, Turkey.

出版信息

ACS Omega. 2023 Oct 5;8(41):38452-38458. doi: 10.1021/acsomega.3c05233. eCollection 2023 Oct 17.

DOI:10.1021/acsomega.3c05233
PMID:37867679
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10586251/
Abstract

Antibiotic resistance is a global health threat. We urgently need better strategies to improve antibiotic use to combat antibiotic resistance. Currently, there are a limited number of antibiotics in the treatment repertoire of existing bacterial infections. Among them, rifampicin is a broad-spectrum antibiotic against various bacterial pathogens. However, during rifampicin exposure, the appearance of persisters or resisters decreases its efficacy. Hence, to benefit more from rifampicin, its current standard dosage might be reconsidered and explored using both computational tools and experimental or clinical studies. In this study, we present the mathematical relationship between the concentration of rifampicin and the growth and killing kinetics of cells. We generated time-killing curves of cells in the presence of 4, 16, and 32 μg/mL rifampicin exposures. We specifically focused on the oscillations with decreasing amplitude over time in the growth and killing kinetics of rifampicin-exposed cells. We propose the solution form of a second-order linear differential equation for a damped oscillator to represent the mathematical relationship. We applied a nonlinear curve fitting solver to time-killing curve data to obtain the model parameters. The results show a high fitting accuracy.

摘要

抗生素耐药性是对全球健康的一大威胁。我们迫切需要更好的策略来改善抗生素的使用,以对抗抗生素耐药性。目前,现有细菌感染的治疗药物中抗生素数量有限。其中,利福平是一种针对多种细菌病原体的广谱抗生素。然而,在接触利福平期间,持留菌或耐药菌的出现会降低其疗效。因此,为了从利福平中获得更多益处,可能需要重新考虑并利用计算工具以及实验或临床研究来探索其当前的标准剂量。在本研究中,我们展示了利福平浓度与细胞生长及杀灭动力学之间的数学关系。我们生成了在4、16和32μg/mL利福平暴露条件下细胞的时间杀灭曲线。我们特别关注了利福平暴露细胞生长和杀灭动力学中随时间振幅减小的振荡。我们提出了一个二阶线性微分方程的解形式来表示阻尼振荡器的数学关系,以描述上述关系。我们将非线性曲线拟合求解器应用于时间杀灭曲线数据以获得模型参数。结果显示拟合精度很高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95ec/10586251/263164694049/ao3c05233_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95ec/10586251/a0291a587910/ao3c05233_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95ec/10586251/bc59d1c0eb3e/ao3c05233_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95ec/10586251/6b0047a7e1d5/ao3c05233_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95ec/10586251/263164694049/ao3c05233_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95ec/10586251/a0291a587910/ao3c05233_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95ec/10586251/bc59d1c0eb3e/ao3c05233_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95ec/10586251/6b0047a7e1d5/ao3c05233_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95ec/10586251/263164694049/ao3c05233_0004.jpg

相似文献

1
Mathematical Model for Growth and Rifampicin-Dependent Killing Kinetics of Cells.细胞生长及利福平依赖性杀伤动力学的数学模型
ACS Omega. 2023 Oct 5;8(41):38452-38458. doi: 10.1021/acsomega.3c05233. eCollection 2023 Oct 17.
2
Unique Mode of Cell Division by the Mycobacterial Genetic Resister Clones Emerging from the Antibiotic-Surviving Population.分枝杆菌遗传抗性克隆从抗生素存活群体中出现的独特细胞分裂模式。
mSphere. 2020 Nov 18;5(6):e00994-20. doi: 10.1128/mSphere.00994-20.
3
Growth and division mechanisms by which genetic resisters emerge from the rifampicin-surviving population of differentially antibiotic-susceptible mycobacterial subpopulations.在对抗生素敏感性不同的分枝杆菌亚群的利福平存活群体中产生基因抗性菌的生长和分裂机制。
Int J Mycobacteriol. 2022 Jul-Sep;11(3):273-286. doi: 10.4103/ijmy.ijmy_88_22.
4
Antibiotic treatment in vitro of phenotypically tolerant bacterial populations.对表型耐受细菌群体进行体外抗生素治疗。
J Antimicrob Chemother. 2007 Feb;59(2):254-63. doi: 10.1093/jac/dkl469. Epub 2006 Nov 13.
5
Most-Probable-Number-Based Minimum Duration of Killing Assay for Determining the Spectrum of Rifampicin Susceptibility in Clinical Mycobacterium tuberculosis Isolates.基于最大可能数法测定临床结核分枝杆菌分离株利福平敏感性谱的最短杀菌持续时间试验
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01439-20.
6
Genetic resisters to antibiotics in Escherichia coli arise from the antibiotic-surviving population containing three reactive oxygen species.大肠杆菌中对抗生素具有遗传抗性的产生源于含有三种活性氧物质的抗生素存活群体。
FEMS Microbiol Lett. 2022 Jan 25;368(21-24). doi: 10.1093/femsle/fnab157.
7
Single Cell Killing Kinetics Differentiate Phenotypic Bacterial Responses to Different Antibacterial Classes.单细胞杀伤动力学可区分不同抗菌类别的细菌表型反应。
Microbiol Spectr. 2023 Feb 14;11(1):e0366722. doi: 10.1128/spectrum.03667-22. Epub 2023 Jan 18.
8
Tolerant Small-colony Variants Form Prior to Resistance Within a Staphylococcus aureus Biofilm Based on Antibiotic Selective Pressure.耐小菌落变异体在基于抗生素选择压力的金黄色葡萄球菌生物膜内形成耐药之前形成。
Clin Orthop Relat Res. 2021 Jul 1;479(7):1471-1481. doi: 10.1097/CORR.0000000000001740.
9
Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime.将药代动力学/药效学时间杀菌研究扩展到包括暴露于头孢呋辛的大肠杆菌中脂多糖/内毒素的释放。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02070-19.
10
Prophages and Growth Dynamics Confound Experimental Results with Antibiotic-Tolerant Persister Cells.噬菌体和生长动态使抗生素耐受持久细胞的实验结果复杂化。
mBio. 2017 Dec 12;8(6):e01964-17. doi: 10.1128/mBio.01964-17.

引用本文的文献

1
Broken beyond repair: TA system ParE toxins mediate effective gyrase inhibition without driving resistance.无法修复:TA系统中的ParE毒素介导有效的促旋酶抑制作用且不会产生耐药性。
J Bacteriol. 2025 Mar 20;207(3):e0041624. doi: 10.1128/jb.00416-24. Epub 2025 Mar 3.

本文引用的文献

1
Intensified Antituberculosis Therapy Regimen Containing Higher Dose Rifampin for Tuberculous Meningitis: A Systematic Review and Meta-Analysis.含高剂量利福平的强化抗结核治疗方案用于结核性脑膜炎:一项系统评价和荟萃分析
Front Med (Lausanne). 2022 Feb 25;9:822201. doi: 10.3389/fmed.2022.822201. eCollection 2022.
2
Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects.微生物的抗生素耐药性:历史、机制、治疗策略和未来前景。
J Infect Public Health. 2021 Dec;14(12):1750-1766. doi: 10.1016/j.jiph.2021.10.020. Epub 2021 Oct 23.
3
Impact of rifampicin on the pharmacokinetics of clarithromycin and 14-hydroxy clarithromycin in patients with multidrug combination therapy for pulmonary Mycobacterium avium complex infection.
利福平对耐多药治疗方案治疗肺鸟分枝杆菌复合体感染患者体内克拉霉素及其 14-羟基代谢物药代动力学的影响。
J Infect Chemother. 2022 Jan;28(1):61-66. doi: 10.1016/j.jiac.2021.10.003. Epub 2021 Oct 25.
4
Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.异烟肼、利福平及吡嗪酰胺在儿童和青少年结核性脑膜炎治疗中的药代动力学和安全性/耐受性。
Arch Dis Child. 2022 Jan;107(1):70-77. doi: 10.1136/archdischild-2020-321426. Epub 2021 Jun 28.
5
Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial.结核性脑膜炎患者高剂量口服与静脉利福平的血浆药代动力学:一项随机对照试验。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0014021. doi: 10.1128/AAC.00140-21.
6
Comparing treatment strategies to reduce antibiotic resistance in an in vitro epidemiological setting.比较体外流行病学环境下减少抗生素耐药性的治疗策略。
Proc Natl Acad Sci U S A. 2021 Mar 30;118(13). doi: 10.1073/pnas.2023467118.
7
Impact of rifampicin dose in bone and joint prosthetic device infections due to Staphylococcus spp: a retrospective single-center study in France.利福平剂量对金黄色葡萄球菌引起的骨与关节假体感染的影响:法国单中心回顾性研究。
BMC Infect Dis. 2021 Feb 12;21(1):174. doi: 10.1186/s12879-021-05832-2.
8
Comparative Effectiveness of Antibiotic Treatment Duration in Children With Pyelonephritis.肾盂肾炎患儿抗生素治疗持续时间的比较效果。
JAMA Netw Open. 2020 May 1;3(5):e203951. doi: 10.1001/jamanetworkopen.2020.3951.
9
Evolution of rifampicin treatment for tuberculosis.利福平治疗结核病的演变。
Infect Genet Evol. 2019 Oct;74:103937. doi: 10.1016/j.meegid.2019.103937. Epub 2019 Jun 24.
10
Discovery of anti-mucoviscous activity of rifampicin and its potential as a candidate antivirulence agent against hypervirulent Klebsiella pneumoniae.发现利福平具有抗黏液活性,并可能成为针对高毒力肺炎克雷伯菌的候选抗毒力药物。
Int J Antimicrob Agents. 2019 Aug;54(2):167-175. doi: 10.1016/j.ijantimicag.2019.05.018. Epub 2019 Jun 5.